SMLR vs. NVCR, CDRE, CNMD, SSII, PLSE, KMTS, BLFS, ESTA, MDXG, and TNDM
Should you be buying Semler Scientific stock or one of its competitors? The main competitors of Semler Scientific include NovoCure (NVCR), Cadre (CDRE), CONMED (CNMD), SS Innovations International (SSII), Pulse Biosciences (PLSE), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), Establishment Labs (ESTA), MiMedx Group (MDXG), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.
Semler Scientific vs. Its Competitors
NovoCure (NASDAQ:NVCR) and Semler Scientific (NASDAQ:SMLR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.
84.6% of NovoCure shares are held by institutional investors. Comparatively, 49.4% of Semler Scientific shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 16.4% of Semler Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
NovoCure presently has a consensus price target of $27.50, suggesting a potential upside of 91.56%. Semler Scientific has a consensus price target of $74.25, suggesting a potential upside of 192.78%. Given Semler Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Semler Scientific is more favorable than NovoCure.
Semler Scientific has a net margin of 86.20% compared to NovoCure's net margin of -27.13%. Semler Scientific's return on equity of 43.84% beat NovoCure's return on equity.
NovoCure has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
In the previous week, Semler Scientific had 14 more articles in the media than NovoCure. MarketBeat recorded 19 mentions for Semler Scientific and 5 mentions for NovoCure. NovoCure's average media sentiment score of 0.20 beat Semler Scientific's score of 0.12 indicating that NovoCure is being referred to more favorably in the media.
Semler Scientific has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.
Summary
Semler Scientific beats NovoCure on 12 of the 15 factors compared between the two stocks.
Get Semler Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMLR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SMLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Semler Scientific Competitors List
Related Companies and Tools
This page (NASDAQ:SMLR) was last updated on 10/16/2025 by MarketBeat.com Staff
